2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 3156

IL17 Promotes Development of Autoreactive Early Stage B Cells in Distinct Regions of the Spleen Follicle
Abstract Number: 3157

B Cell Profile As a Biomarker of Disease Segmentation and Flare Prognosis in SLE
Abstract Number: 3158

Impact of Family History of Systemic Lupus Erythematosus on Risk of Autoimmune Diseases: National Cohort Study in Denmark 1977-2012
Abstract Number: 3159

Systemic Lupus Erythematosus Is a Risk Factor for Young Stroke: A Population-Based Cohort Study
Abstract Number: 3160

Comparative Rates of Serious Infections and All-Cause Mortality Among Systemic Lupus Erythematosus Patients Receiving Mycophenolate Mofetil Versus Azathioprine
Abstract Number: 3161

Rates of Hospitalization for Infection and Related Mortality By Race/Ethnicity and Sex Among Patients with End-Stage Renal Disease Due to Systemic Lupus Erythematosus
Abstract Number: 3162

Prevalence of Chronic Comorbidities in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Systemic Lupus Erythematosus: An Analysis of UK Biobank Data
Abstract Number: 3163

The Smoking Paradox in the Development of Psoriatic Arthritis Among Psoriasis Patients
Abstract Number: 3164

Calcium Pyrophosphate Deposition Disease and Associated Medical Co-Morbidities in the Veteran Population
Abstract Number: 3165

Do Omega-3 Fatty Acids Reduce Risk of Recurrent Gout Attacks?
Abstract Number: 3166

Epistatic Interaction of Functional Inflammasome Genetic Variants in Determining the Risk of Gout
Abstract Number: 3167

Association of the Apolipoprotein A1-C3-A4 Gene Cluster with the Risk of Gout: Evidence for a Causal Role in Gout
Abstract Number: 3168

How Strong Cardiovascular Risk Factor Are Gouty Tophi?
Abstract Number: 3169

Diagnostic Value of Ultrasound for the Diagnosis of Gout in a Prospective Cross-Sectional Study
Abstract Number: 3170

Peripheral Osteoblastogenesis in Rheumatoid Arthritis Is Enhanced after TNF Blocker Treatment, Irrespective of Systemic Inflammation

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].